Records containing: Multiple Myeloma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-11-26Covid-19 Vaccine Responsiveness in Patients With Multiple Myeloma and Waldenstrom's Macroglobulinemia
-
CLINICAL_TRIALS study record update · 2025-11-26Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
-
CLINICAL_TRIALS study record update · 2025-11-25ELDORADO: a Randomized Phase II Trial of Elranatamab or Daratumumab in Combination With Lenalidomide, Bortezomib, and Dexamethasone (RVd Lite) in Newly Diagnosed, Transplant Ineligible/Deferred Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-11-25Exploratory Clinical Study on the Safety and Efficacy of CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-11-24Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-11-24DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
-
CLINICAL_TRIALS study record update · 2025-11-24A Prospective Non-interventional Post-authorization Safety Study (PASS) of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant ("Transplant Noneligible" [TNE])
-
CLINICAL_TRIALS study record update · 2025-11-24A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial
-
CLINICAL_TRIALS study record update · 2025-11-21The Effect of Distance Reiki on Patient Reported Quality of Life, Correlated With Changes in Immune Repertoires Among Multiple Myeloma Patients: A Pilot Study
-
CLINICAL_TRIALS study record update · 2025-11-20Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study
-
CLINICAL_TRIALS study record update · 2025-11-20Intracellularly Prepared Chimeric Antigen Receptor T-cell Therapy Targeting CD19 for the Treatment of Relapsed/Refractory Hematological Malignancies
-
CLINICAL_TRIALS study record update · 2025-11-20An Open Label, Phase 1 Study Evaluating the Activity of Modular CAR T for mYeloma
-
CLINICAL_TRIALS study record update · 2025-11-20Registry for Adults With Plasma Cell Disorders (PCD's)
-
CLINICAL_TRIALS study record update · 2025-11-19Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-11-19The Effect of Novel Treatments in Improving Renal Outcomes Among Patients With Light Chain Cast Nephropathy
-
CLINICAL_TRIALS study record update · 2025-11-19Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
-
CLINICAL_TRIALS study record update · 2025-11-18Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-11-13Microbial Changes in Response to a Plant Based Diet and/or Supplements in SMM/MGUS Patients: A National Multi-Arm Randomized Prospective Telehealth Study Via HealthTree
-
CLINICAL_TRIALS study record update · 2025-11-12Pilot PET Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-11-12Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
-
CLINICAL_TRIALS study record update · 2025-11-12A Phase 2, Multicenter, Open Label, Non-randomized Study to Evaluate the Efficacy and Safety of Extended Dosing of Belantamab Mafodotin in Different Combinations With Standard of Care Regimens in Participants With Relapsed-refractory Multiple Myeloma (DREAMM-15)
-
CLINICAL_TRIALS study record update · 2025-11-10Sleep Apnea in Patients With MGUS and MM
-
CLINICAL_TRIALS study record update · 2025-11-10ClinicalTrials.gov study NCT05164250
-
CLINICAL_TRIALS study record update · 2025-11-10Long-term Follow-up Study of Patients Receiving CAR-T Cells
-
CLINICAL_TRIALS study record update · 2025-11-06A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5